Benzinga’s Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022, in Miami, Florida.
Understanding The Psilocybin Supply Chain: Every Production Method Explained
Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material.
As psychedelics-assisted therapy gains momentum, investors need to understand the difference between the current available means of obtaining psilocybin.
Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders
Mydecine Innovations Group (NEO:MYCO) (OTC: MYCOF) (FSE:0NFA) reported its financial results on Tuesday and provided a business update for the third quarter ended September 30.
The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
Dr. Aaron T. Beck, the father of cognitive therapy, died on Monday at his home in Philadelphia at age 100.
Historic: Federal Agency Awards Grant For Psychedelics Research, First Time In 50 years
The National Institutes of Health awarded a nearly $4 million grant meant to fund research on psilocybin, the active ingredient in “magic mushrooms,” to researchers at Johns Hopkins University.
Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval
Psychedelics and mycology company Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) is poised to wrap up the spin-out of its U.S. cannabis assets into a newly formed subsidiary.
PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
On Wednesday, PharmaDrug Inc. (CSE: PHRX) (OTCPINK: LMLLF), a company researching DMT and other psychedelics for medical purposes, announced a new clinical trial agreement with Johns Hopkins University, one of the leading research institutions in the space.
Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
Beckley Psytech Closes $80 Million Series B